Search clinical trials for: AZD1208

Total 81 results

AstraZeneca

Completed

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Advanced Solid Malignancies | Malignant Lymphoma

United Kingdom, Japan
AstraZeneca

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

Acute Myeloid Leukemia

United States, Canada
AstraZeneca

Terminated

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Gastric Cancer | Advanced Solid Malignancies | Solid Tumour | Child-Pugh A to B7 Advanced Hepatocellular Carcinoma | EGFR and/or ROS Mutant NSCLC | Lung Metastasis Carcinoma

Korea, Republic of
Imperial College London
AstraZeneca; University of Oxford

Active, not recruiting

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (COVAXAER01)

Covid19 | SARS-CoV-2 Infection

United Kingdom
AstraZeneca

Terminated

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Solid Malignancies

United States
AstraZeneca

Completed

AZD6280 Multiple Ascending Dose Study (MAD)

Healthy Volunteer

United States
AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
AstraZeneca

Completed

Cardiac Electrophysiological Study

Atrial Flutter

Finland, Norway, Denmark, Sweden
AstraZeneca

Completed

Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305

Healthy

United Kingdom
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704

Pain

United Kingdom
AstraZeneca

Completed

Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients (CERA)

Chronic Obstructive Pulmonary Disease

Bulgaria, Germany, Hungary, Finland, Slovakia
AstraZeneca

Completed

Multiple Ascending Dose Study for AZD 7268 in Japanese Healthy Male Volunteers (JMAD)

Healthy

Japan
AstraZeneca

Completed

Study of an Extended Release (ER) Tablet, Single and Repeated Dosing

Healthy

Sweden
AstraZeneca

Completed

Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305 (2007-005765-38)

Healthy

United Kingdom
AstraZeneca

Completed

A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients (BICO)

Chronic Obstructive Pulmonary Disease

Denmark, Finland, Norway, Netherlands
AstraZeneca

Completed

AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects (JSAD)

Healthy

United States
AstraZeneca

Terminated

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects (JMAD)

Healthy

United States
University of Edinburgh
NHS Lothian

Completed

Imaging FIB ONE in the Human Lung Using Endomicroscopy (FIB ONE)

Fibrosis | Lung Cancer

United Kingdom
Dizal Pharmaceuticals

Completed

A Study of AZD4205 in Healthy Adult Subjects (JACKPOT2)

Healthy Volunteers

United States
AstraZeneca

Completed

Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305

Atrial Fibrillation

Sweden, Czech Republic, Hungary, Poland, Netherlands, Norway, Denmark, Slovakia
AstraZeneca

Completed

Explorative Study of AZD1305 in Atrial Fibrillation Patients

Atrial Fibrillation

Russian Federation, Poland, Denmark, Norway, Slovakia, Sweden
AstraZeneca

Terminated

Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236

Healthy Volunteer

Japan
AstraZeneca

Withdrawn

Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis (CYBER)

Cystic Fibrosis

Netherlands, Poland, Spain, Canada
Dizal Pharmaceuticals

Recruiting

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Non-small Cell Lung Cancer

China
AstraZeneca
RTI Health Solutions

Completed

EU Secondary Data Post-Authorisation Safety Study of AZD1222 (D8111R00006)

COVID-19, Vaccine Adverse Events of Special Interest

Netherlands, Spain, United Kingdom
AstraZeneca

Recruiting

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Breast Cancer | Ovarian Cancer | Endometrial Cancer | Biliary Tract Carcinoma

United States, Spain, Australia, United Kingdom, Korea, Republic of, Belgium, Canada, China, Japan, Taiwan, Thailand, Hungary, Poland, Netherlands
Dizal Pharmaceuticals

Completed

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Relapsed or Refractory Peripheral T Cell Lymphoma

Korea, Republic of, United States, China, Australia
AstraZeneca
Covance; Iqvia Pty Ltd

Withdrawn

AZD1222 Vaccine for the Prevention of COVID-19

COVID-19

Russian Federation
Federal University of Espirito Santo
Instituto René Rachou/Fiocruz; Escola Nacional de Saúde Pública Sérgio Arouca... and other collaborators

Recruiting

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

SARS-CoV-2

Brazil
Dizal Pharmaceuticals

Completed

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer (JACKPOT1)

Nonsmall Cell Lung Cancer

Australia
AstraZeneca

Completed

Single Ascending Dose Study (SAD) iv Formulation (2006-006253-27)

Healthy

Sweden
Chang Gung Memorial Hospital

Recruiting

Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

Healthy | Covid-19 | Vaccine | Immunogenicity | Reactogenicity

Taiwan
Albert B. Sabin Vaccine Institute
Stanford University; Aga Khan University; Oswaldo Cruz Foundation

Completed

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

COVID-19

Brazil, Pakistan
AstraZeneca

Completed

To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

Healthy

United Kingdom
AstraZeneca

Completed

AZD8108 SAD/MAD in Healthy Volunteers (AZD8108)

Healthy Volunteers

United States
AstraZeneca

Terminated

Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects

Healthy

United Kingdom
AstraZeneca

Completed

Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects

Healthy Volunteer

United States
AstraZeneca
Parexel

Not yet recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
Istituto Auxologico Italiano
YGHEA, CRO Division of Ecol Studio spa; Apnimed Inc.; STM Pharma PRO srl

Completed

Study of AD128 Versus Placebo in Obstructive Sleep Apnea

Obstructive Sleep Apnea

Italy
Humanity & Health Medical Group Limited

Completed

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Chronic Liver Disease

Hong Kong
AstraZeneca

Completed

To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects

Healthy

Japan
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
Federal University of Espirito Santo
Instituto René Rachou/Fiocruz

Recruiting

COVID-19 VACCINE SAFETY AND EFFECTIVENESS

SARS-CoV-2 Infection

Brazil
AstraZeneca
Iqvia Pty Ltd

Completed

Study of AZD1222 for the Prevention of COVID-19 in Japan

COVID-19

Japan
R-Pharm
AstraZeneca; Russian Direct Investment Fund; The Gamaleya National Center of...

Completed

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

COVID-19

Russian Federation
AstraZeneca

Completed

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

Left Ventricle Function

Sweden
Shabir Madhi
AstraZeneca

Completed

Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death

COVID-19 | Pneumonia, Viral

Swaziland
AstraZeneca

Completed

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

Asthma

United Kingdom

3

Subscribe